Search Results 421-430 of 14754 for anti-TNF drugs

  1. Tofacitinib (Oral Route) Precautions - Mayo Clinic

    Precautions. Drug information provided by: Merative, Micromedex®. It is very important that your doctor check your progress at regular visits. This will ...

  2. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

    History of systemic anti-cancer therapy (e.g., chemotherapy, targeted therapy) ... therapy for treatment of metastatic disease. ... TNF] factor agents) within 14 ...

  3. Neuroendocrine tumors - Diagnosis and treatment - Mayo Clinic

    Treatment · Surgery. Surgery is used to remove the tumor. · Chemotherapy. Chemotherapy uses strong drugs to kill tumor cells. · Targeted drug therapy. · Peptide ...

  4. A Study to Evaluate TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD) - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name. Search tips ... This includes anti-tumor necrosis factor-alpha (TNF ...

  5. Gene therapy - Mayo Clinic

    It holds promise as a treatment for a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. The U.S. Food and ...

  6. Golimumab (Intravenous Route, Subcutaneous Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  7. Irinotecan (Intravenous Route) Description and Brand Names - Mayo Clinic

    Irinotecan injection is given together with other medicines (eg, 5-fluorouracil, leucovorin) to treat patients with metastatic cancer (a cancer that has already ...

  8. Fentanyl (Transdermal Route) Precautions - Mayo Clinic

    This medicine will add to the effects of alcohol and other CNS depressants. CNS depressants are medicines that slow down the nervous system, which may cause ...

  9. Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior Chronic Myeloid Leukemia Therapies - Mayo Clinic

    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior Chronic Myeloid Leukemia Therapies.

  10. Publications - Melanie D. Swift, M.D., M.P.H. - Mayo Clinic

    ... Anti-TNF Therapy After COVID-19 Vaccination. Inflamm Bowel Dis. 2023 Aug 1; 29 (8):1202-1209. View PubMed; Khan Jamal, Ashbeck RA, Breeher LE, Swift MD, Hainy ...